Doug Monroe of Kaiser Permanente's 2015 Presentation

Kaiser Permanente: the impact of biosimilars on private reimbursement

We were excited to have Doug Monroe, Project Manager of Biotechnology, Emerging Technology, and Specialty Pharmacy at Kaiser Permanente, share¬†his expertise on the impact of biosimilars on private reimbursement strategies at the World Biosimilar Congress USA. Download his presentation now > You can now download Doug’s presentation to find out more about: The Kaiser Permanente integrated health care delivery system …

Victoria the pro-biotech state is about to raise the cost of clinical trials

It has been reported that the Victorian Managed Insurance Authority from July 1 will be increasing the insurance requirements for commercial sponsors of human clinical trials in Victoria. As a state that has always been seen to encourage clinical trials, it has come as a shock that future projects may be hindered due to increased insurance costs.  It seems that …